ArticleClinicoEconomics and outcomes research : CEOR2024

Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective.

Bjoern Schwander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.